SAB4200346

Anti-SMAD7 (N-terminal) antibody produced in rabbit

~1.0 mg/mL, affinity isolated antibody, suitable for western blot: 2 μg/mL

• Synonim(y): Anti-CRCS3, Anti-MAD homolog 7, Anti-MAD homolog 8, Anti-MADH7, Anti-MADH8, Anti-Mothers against DPP homolog 7, Anti-Mothers against DPP homolog 8, Anti-SMAD
• Kod UNSPSC: 12352203
• NACRES: NA.41

Właściwości

• pochodzenie biologiczne: rabbit
• białko sprzężone: unconjugated
• forma przeciwciała: affinity isolated antibody
• rodzaj przeciwciała: primary antibodies
• klon: polyclonal
• Postać: buffered aqueous solution
• masa cząsteczkowa: antigen ~46 kDa
• reaktywność gatunkowa: human
• stężenie: ~1.0 mg/mL
• metody: indirect immunofluorescence: 1-2 μg/mL using human A549 cells.; western blot: 2-4 μg/mL using whole extracts of HEK-293 cells over-expressing human SMAD7.
• numer dostępu UniProt: O15105
• Warunki transportu: dry ice
• temp. przechowywania: −20°C
• docelowa modyfikacja potranslacyjna: unmodified
• informacje o genach: human ... SMAD7(4092)

Opis

Opis ogólny

SMAD7 (mothers against decapentaplegic homolog 7) is a Tbx1 (T-box 1) interacting gene and is encoded by the gene mapped to human chromosome 18q21.1.

SMAD7 (mothers against decapentaplegic homolog 7), that binds the E3 ubiquitin ligase Smurf1/2. SMAD7 belongs to the family of inhibitory Smads (I-Smads).

Immunogen

peptide corresponding to the N-terminal region of human SMAD7, conjugated to KLH. The corresponding sequence is identical in monkey and differs by 2 amino acids in mouse and rat.

Zastosowanie

Anti-SMAD7 (N-terminal) antibody produced in rabbit has been used in immunoblotting and immunofluorescence.

Działania biochem./fizjol.

SMAD7 (mothers against decapentaplegic homolog 7) is a modulator of TGFβ (transforming growth factor β) signaling in immune cells which are associated with ulcerative colitis and inflammatory bowel syndrome. It plays a major role in the etiology of CRC (colorectal cancer). In addition, it also acts as a mediator of the negative feedback loop for both the TGFβ and BMP (bone morphogenetic proteins) signaling pathways. It is essential for the remodelling of pharyngeal artery and the enlargement of great vessel. In mouse, homozygous removal of Smad7 causes primarily fourth-related arch artery defects. Silencing of Smad7 in RCD (refractory coeliac disease) biopsy samples can decrease the expression of interleukin-6 and tumour necrosis factor-α. Polymorphism of this gene is associated with colorectal cancer. SMAD7 is an inhibitor of the TGFβ (transforming growth factor beta) /BMP (bone morphogenetic proteins) pathway.

Postać fizyczna

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

Oświadczenie o zrzeczeniu się odpowiedzialności

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Informacja o środkach bezpieczeństwa

• Kod klasy składowania: 10 - Combustible liquids
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable